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Abstract
Chronic pulmonary disease is a recognized risk factor for invasive pneumococcal disease (IPD). However, previous studies have often not
been large enough to allow detailed analyses of less prevalent pulmonary diseases, and ﬁndings regarding case fatality have been inconsistent.
We examined the associations between an underlying pulmonary disease and IPD, and the impact of these diseases on the case fatality rate.
Patients with IPD  18 years of age, between 1990 and 2008, were identiﬁed in microbiological databases. The associations between IPD
and the pulmonary diseases were assessed using conditional logistic regression, comparing IPD cases to ten control subjects per case,
randomly selected from the general population (matched for gender, year of birth and county of residence). Adjustments were made for
other co-morbidities, level of education and socio-economic status, 4085 cases of IPD and 40 353 controls were identiﬁed. A more than
four-fold increased risk of IPD was seen in chronic obstructive pulmonary disease, a doubled risk in asthma and a ﬁve-fold increased risk in
subjects with pulmonary ﬁbrosis. In univariate analysis, sarcoidosis and bronchiectasis were associated with a two-fold to seven-fold
increase in the risk of IPD, but there was no statistical support for the associations when adjustments for confounders were made. No
increased risk was seen in subjects with a history of pneumoconiosis or allergic alveolitis. The mortality following IPD was not increased in
patients with chronic obstructive pulmonary disease, asthma, pulmonary ﬁbrosis or bronchiectasis. Several chronic pulmonary diseases
increase the risk of IPD but mortality following IPD seems not to be affected.
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Introduction
Streptococcus pneumoniae is an encapsulated Gram-positive
pathogen with the potential to cause invasive disease. It is a
major cause of community-acquired pneumonia and bacterial
meningitis. In Sweden, invasive pneumococcal disease (IPD) has
been a notiﬁable disease since 2004, and around 1500 cases
are reported annually to the Swedish Institute for Communi-
cable Disease Control, corresponding to an annual incidence
of 15–19 cases/100 000 inhabitants [1].
Chronic obstructive pulmonary disease (COPD) and,
recently, asthma [2] are recognized risk factors for acquiring
IPD, but risk estimates published in previous studies are often
based on case series or studies with aggregated denominator
data on co-morbidities, and have in many cases, not been large
enough to allow multivariate analysis or detailed analysis of less
prevalent pulmonary diseases [3,4]. In addition, it is not clear
whether an underlying pulmonary disease increases the risk of
death following IPD [3,5,6].
In this large population-based case–control study, nested in
the population of southern Sweden, an area with around 1.6
million inhabitants, we examined the association between a
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history of chronic pulmonary disease and IPD, and the effect of
underlying pulmonary diseases on mortality following IPD,
comparing IPD cases with randomly selected control subjects
from the general population.
Methods
Ethics
The study was approved by the Lund University Research
Ethics Committee (203/2008, 223/2009, 398/2011).
Setting
Swedish health care is publicly ﬁnanced, with few private
care-givers in secondary care. A unique, lifelong ten-digit
personal identity number assigned to each person living in
Sweden provides the possibility of cross-referencing informa-
tion in national databases.
Case retrieval and control selection
All individuals  18 years of age, living in southern Sweden,
showing growth of S. pneumoniae in a culture from a normally
sterile site (e.g. blood, cerebrospinal ﬂuid, pleural effusion)
were identiﬁed in the databases at the seven microbiological
laboratories covering the area (Kristianstad 1991–2008, Lund
1991–2008, Malm€o 1990–2008, Halmstad 1995–2008, Kalmar
1990–2008, Karlskrona 1994–2008 and V€axj€o 1987–2008). For
each case, ten control subjects were randomly selected from
the general population, matched for gender, year of birth and
county of residence on 31 December the year before the
diagnosis of IPD. All cases and controls were cross-referenced
to national databases to obtain personal information on vital
status, and information on level of education and socio-eco-
nomic status.
Co-morbidity
Through linkage with the National Inpatient Registry and the
Cancer Registry information was obtained on all available
hospital discharge and cancer diagnoses. The Inpatient Registry
has been operating in southern Sweden since the early 1970s,
apart from the counties of Kronoberg (1987) and Blekinge
(1984). It came into operation nationwide in 1987. Visits to
hospital outpatient clinics and emergency departments have
been recorded nationwide since 2001.
The following chronic pulmonary diseases were taken
into consideration: COPD, asthma, pulmonary ﬁbrosis,
sarcoidosis, bronchiectasis, allergic alveolitis and pneumoco-
niosis registered >30 days to 5 years before the ﬁrst IPD
diagnosis or the corresponding date in control subjects. In
addition, we noted discharge diagnoses of other non-pul-
monary diseases conferring increased risk of IPD, liver
disease, renal failure, heart failure, cerebrospinal ﬂuid
leakage, rheumatoid arthritis and other connective tissue
diseases, alcohol-related diseases, diabetes mellitus, haema-
tological and non-haematological cancer, human immunode-
ﬁciency virus infection and immunodeﬁciency [4]. Codes for
transplantation and splenectomy were noted for the total
Inpatient Registry period up to 30 days before index. The
speciﬁc codes according to the International Classiﬁcation of
Diseases can be found in the Supplementary information,
Appendix S1.
Chart review
General validation studies of the Inpatient Registry indicate
that coverage is above 98% and that almost 90% of the
diagnoses reported are correct [7]. We have previously
validated the diagnosis of COPD in the Inpatient Registry in
this cohort. The degree of certainty of the diagnosis varied, but
< 10% were considered misclassiﬁed or having an uncertain
COPD diagnosis [8]. A subset of the other pulmonary
diagnoses from the four major hospitals in the county of
Skane (Helsingborg, Kristianstad, Lund and Malm€o), was
validated against the original medical records. The estimated
diagnostic accuracy was as follows: asthma (n = 198) 80%,
sarcoidosis (n = 17) 95%, pneumoconiosis (n = 7) 100%,
pulmonary ﬁbrosis (n = 41) 85% and bronchiectasis (n = 13)
85%.
Statistical analyses
Chi-squared tests, Fisher’s exact test and t-tests were used
to assess the risk factors for IPD and risk factors for
in-hospital mortality and death within 28 days of IPD
diagnosis. The associations between IPD and underlying
pulmonary diseases were assessed using conditional logistic
regression. Separate models were ﬁtted for each pulmonary
disease. Adjustments were made for other chronic non-pul-
monary diseases, total duration of hospital stay, level of
education and socio-economic status. Interactions between
disease status, age at inclusion, gender and time since the
previous hospital visit for pulmonary disease, on outcome
were assessed by examining odds ratios in different strata of
the covariates and by including interaction terms in the fully
adjusted models.
The associations between death within 28 and 90 days of
IPD diagnosis and underlying lung disease were assessed using
logistic regression, adjusted for age, gender, clinical presenta-
tion and other co-morbidities. Likelihood ratio tests were
performed to test for differences and interactions. All analyses
were performed using STATA/SE (version 10.1 for Windows;
StataCorp LP, College Station, USA).
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Results
A ﬁrst episode of IPD was identiﬁed in 4135 individuals
 18 years of age, corresponding to an average rate of 16/
100 000 annually. In the control group, 185 individuals were
excluded because of suspected reused personal identiﬁcation
numbers, and another 708 individuals because of death before
the date of diagnosis of the corresponding cases. Fifty of the IPD
cases and 96 control subjects had records of both COPD and
asthma and were excluded from the main analyses. A total of
4085 cases and 40 353 matched controls were subjected to the
ﬁnal analyses.
The median age at inclusion was 67 years (range 18–
103 years), and 49.4% were men. Among the cases, 96.4% had
bacteraemia, 3.2% had pneumococcal growth in the cerebro-
spinal ﬂuid (with or without bacteraemia) and 2.4% positive
culture from other normally sterile sites (with or without
bacteraemia). According to the hospital discharge codes in the
Inpatient Registry, 70.7% of the IPD cases had pneumonia, 5.9%
had meningitis, 2% had miscellaneous foci (e.g. arthritis,
peritonitis etc.), and 21.5% had no speciﬁc focus (i.e. primary
bacteraemia or no recorded focus).
Overall 39.5% of the IPD cases had a hospital contact for
any of the recorded diseases, >30 days to 5 years before ﬁrst
IPD diagnosis, as compared with 19.5% among control subjects
(p <0.001). The demographic characteristics are given in
Table 1. The speciﬁc odds ratios for IPD in patients with
underlying diseases are outlined in Table 2.
COPD
In total, 726 individuals, of whom 57.9% were men, had a
history of COPD. Among the cases, 248 (6.1%) had a history
of COPD, whereas the corresponding number among the
control subjects was 478 (1.2%). This corresponds to a
ﬁve-fold increase in the risk of acquiring IPD, after adjust-
ment for other co-morbidity, level of education and
socio-economic status. The results are outlined in detail in
Table 3.
The risk of IPD increased with the total number of previous
hospital visits for COPD (p <0.001 for trend), and decreased
with time since the preceding hospital visit for COPD (p <0.01
for trend), as illustrated in Figure 1. Evidence was found of an
interaction between COPD status and age at index (p 0.01),
but not with gender or socio-economic status.
Asthma
In total, 380 individuals, of whom 36.3% were men, had a
previous diagnosis of asthma: 71 (1.7%) among the IPD cases
and 309 (0.8%) among the controls. This corresponds to
a two-fold increase in the risk of IPD when adjusted for other
co-morbidity, level of education and socio-economic status.
There was an overlap between asthma and COPD, as
mentioned above. However, repeating the analyses including
individuals with records of both COPD and asthma, adjusting
for both, only lowered the estimates slightly: COPD aOR 4.3,
95% CI 3.6–5.1, asthma aOR 1.6, 95% CI 1.3–2.0.
Other chronic pulmonary diseases
A history of pulmonary ﬁbrosis was associated with a ﬁve-fold
increase in risk of IPD (Table 3). Previous sarcoidosis and
bronchiectasis was associated with a two-fold to seven-fold
increase in the risk of IPD in univariate analysis, but there was
no statistical support for the associations when adjustments
were made for co-morbidity, level of education and socio-eco-
nomic status. There was no evidence of an association with a
history of pneumoconiosis or allergic alveolitis (Table 3).
TABLE 1. Demographic characteristics of the study popula-
tion
IPD cases
n = 4085 (100%)
Control subjectsa
n = 40 353 (100%) p-value
Age category
18–59 years 1418 (34.7%) 14 142 (35.1%)
60–79 years 1717 (42.0%) 17 167 (42.5%)
 80 years 950 (23.3%) 9044 (22.4%)
Gender
Male 2018 (49.4%) 19 900 (49.3%)
Level of education < 0.01
Primary education 1471 (36.0%) 14 323 (35.5%)
Secondary education 1254 (30.7%) 11 488 (28.5%)
Upper secondary
education
814 (19.9%) 8152 (20.2%)
College/University 341 (8.4%) 4489 (11.1%)
No information 205 (5.0%) 1900 (4.7%)
Socio-economic status < 0.01
Non-manual 748 (18.3%) 8622 (21.4%)
Manual 939 (23.0%) 9236 (22.9%)
Other 332 (8.1%) 3353 (8.3%)
Outside workforceb 2066 (50.6%) 19 142 (47.4%)
Co-morbidityc
Previous hospitalization 2442 (59.8%) 16 372 (40.6%) <0.01
Total duration of hospital stay
Mean/median (days)d 23.7/5 11.1/0 <0.01
Heart failure 333 (8.1%) 1387 (3.4%) <0.01
Liver disease 56 (1.4%) 88 (0.2%) <0.01
Renal failure 62 (1.5%) 128 (0.3%) <0.01
CSF leakage 0 0 NA
Connective tissue
disease
181 (4.5%) 579 (1.5%) <0.01
Alcohol-related
disease
124 (3.0%) 292 (0.7%) <0.01
Diabetes mellitus 298 (7.3%) 1369 (3.4%) <0.01
HIV 10 (0.2%) 3 (0.01%) <0.01
Immunodeﬁciency 17 (0.4%) 22 (0.05%) <0.01
Haematological cancer 200 (4.9%) 101 (0.3%) <0.01
Solid cancer 243 (6.0%) 1538 (3.8%) <0.01
Splenectomye 4 (0.1%) 1 (0.00) <0.01
Transplant recipient 21 (0.5%) 22 (0.05%) <0.01
CSF, cerebrospinal ﬂuid; HIV, human immunodeﬁciency virus; IPD, invasive
pneumococcal disease.
aControl subjects were matched for year of birth, gender and county of residence
on 31 December the year before IPD diagnosis.
bSubjects with no information on socio-economic status were mainly retired,
unemployed, living on disability beneﬁt, homemakers or students.
cCo-morbidity recorded >30 days to 5 years before ﬁrst positive culture and the
corresponding date in the control subjects, see Appendix S1 for speciﬁc
International Classiﬁcation of Diseases codes.
d>30 days up to 5 years before ﬁrst positive culture.
eCodes of splenectomy and transplantation were recorded for the total registry
period up to >30 days before index.
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Mortality following IPD
Among the 4085 IPD cases, 495 (12.1%) died within 28 days of
the ﬁrst positive culture, 618 (15.1%) died within 90 days. The
median age at death was 77 years (range 30–103 years). The
all-cause mortality risk within 28 days varied with clinical
presentation (meningitis 20.8%, pneumonia 8.2%, miscellaneous
foci 3.8% and primary bacteraemia (or no recorded focus)
24.4%).
A previous diagnosis of COPD, asthma, pulmonary ﬁbrosis
or bronchiectasis was not associated with death within 28 or
90 days, according to logistic regression models adjusting for
age, gender, clinical presentation and other co-morbidity. The
modest number of subjects with sarcoidosis, pneumoconiosis
or allergic alveolitis among IPD patients, prevented any reliable
inferences concerning mortality risk.
Discussion
In this population-based study on > 4 000 individuals with IPD,
we were able to conﬁrm that the risk of IPD is independently
increased for patients suffering from COPD and asthma.
TABLE 2. The relationship between risk factors and invasive
pneumococcal disease
Univariate
OR (95% CI)a
Multivariate
OR (95% CI)b
Level of education
Primary education 1 1
Secondary education 1.9 (1.2–2.9) 1.9 (1.2–3.0)
Upper secondary education 1.7 (1.1–2.6) 1.8 (1.1–2.38
College/University 1.3 (0.8–2.0) 1.4 (0.9–2.3)
No information 1.7 (1.1–2.5) 1.5 (1.0–1–0)
Socio-economic status
Non-manual 1 1
Manual 1. (1.1–1.3) 1.0 (0.9–1.2)
Other 1.2 (1.0–1.3) 1.1 (0.9–1.2)
Outside workforcec 1.4 (1.2–1.5) 1.1 (1.1–1.3)
Co-morbidityd
Any chronic pulmonary disease 4.4 (3.9–5.1) 3.6 (3.1–4.1)
Heart failure 2.5 (2.2–2.9) 1.7 (1.4–1.9)
Liver disease 6.3 (4.5–8.9) 3.8 (2.6–5.5)
Renal failure 5.0 (3.7–6.8) 3.0 (2.1–4.3)
Connective tissue disease 3.2 (2.7–3.9) 2.7 (2.3–3.3)
Alcohol-related disease 4.4 (3.6–5.5) 3.8 (3.0–4.7)
Diabetes mellitus 2.3 (2.0–2.6) 1.7 (1.5–1.9)
Human immunodeﬁciency virus 50.0 (11.0–228.1) 53.0 (11.5–244.4)
Immunodeﬁciency 7.6 (4.0–14.4) 1.4 (0.7–3.1)
Haematological cancer 20.5 (16.1–26.3) 19.7 (15.3–25.5)
Solid cancer 1.6 (1.4–1.8) 1.5 (1.3–1.7)
Splenectomy 8.2 (5.7–12.0) 6.2 (4.0–9.4)
Transplant recipient 9.4 (5.2–17.2) 2.1 (1.0–4.4)
Total days of hospitalization 1.0 (1.0–1.0) 1.0 (1.0–1.0)
aOdds ratio for invasive pneumococcal disease for the speciﬁc diseases compared
with not having the disease, estimated using a conditional logistic regression
model.
bOdds ratio for invasive pneumococcal disease for the speciﬁc diseases compared
to not having the disease, estimated using a conditional logistic regression model
adjusting for all other variables in the table: from likehood ratio test.
cSubjects with no information on socio-economic status were mainly retired,
unemployed, living on disability beneﬁt, homemakers or students.
dCo-morbidity recorded >30 days to 5 years before ﬁrst positive blood culture
with IPD and the corresponding date in the control subjects, see Appendix S1 for
speciﬁc International Classiﬁcation of Diseases codes, codes of splenectomy and
transplantation were recorded for the total registry period up to >30 days before
index.
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Surprisingly, we found an even higher risk in individuals with a
diagnosis of pulmonary ﬁbrosis. Despite the increased risk of
acquiring IPD, the risk of mortality following IPD was not
increased in those with a previous record of COPD, asthma,
pulmonary ﬁbrosis or bronchiectasis.
Increasing age-speciﬁc IPD incidence rates have previously
been reported in patients with chronic lung diseases (a joint
effect of age and pulmonary disease) [4]. In our study, the
independent effects of COPD and asthma were found to be
attenuated with increasing age. This could be attributed to a
relatively higher proportion of frail individuals in general in
older age groups, diminishing the difference between having a
pulmonary disease or not. It could also reﬂect a higher
proportion of patients with less severe pulmonary disease
(“survivors”) in older age groups.
A combination of host factors and the virulence of the
microbe determines the outcome after an encounter with a
pathogen. In COPD, innate defence mechanisms in the
airways are impaired, mainly by a decrease in mucociliary
clearance but several additional mechanisms have been
described [9–11]. In addition, the increased risk of IPD in
patients with pulmonary disease could partly be mediated by
factors such as smoking or immunosuppressive treatment
(e.g. corticosteroids).
Smokers have been shown to have an increased risk of
IPD in various settings, although it may be difﬁcult to
establish the independent effect (not mediated, e.g. through
COPD) [12]. The prevalence of smoking in Sweden declined
from 25% to 14% between 1990 and 2007 [13]. The current
smoking rate in patients diagnosed with COPD in Sweden
has been estimated to be around 31%, whereas a survey of
COPD patients in specialist care showed that 23% were still
smokers [14,15]. Pulmonary ﬁbrosis and pneumoconiosis are
associated with increased smoking rates, whereas sarcoidosis
and allergic alveolitis are more common in non-smokers
[16,17].
Oral treatment with corticosteroids increases the risk of
severe infections, although the underlying disease severity is an
important modiﬁer [18]. In a pooled analysis of 14 controlled
clinical trials concerning individuals with pulmonary diseases,
no increase in infectious complications was seen [18]. How-
ever, an increased risk of pneumonia has been reported from
meta-analyses of inhaled corticosteroids [19,20], although, no
increased risk was reported in pooled analyses of asthma or
COPD trials using budesonide [21].
Some patients with pulmonary ﬁbrosis have episodes of
rapid deterioration. The majority of these are the result of
exacerbations (without any signs of infection) but infectious
episodes have been estimated to be the second most
important cause [22]. Increased bacterial colonization of the
lower airways has been demonstrated [23], and 3 to 14% of
deaths in patients with pulmonary ﬁbrosis have been attributed
to pulmonary infections [24,25].
Registry-based designs have limitations. The Swedish, pub-
licly ﬁnanced healthcare system ensures that all patients
receiving hospital-based care were captured. But patients only
treated in primary care were not included. The sensitivity of
detecting chronic pulmonary diseases in the Inpatient Registry
was assumed to be non-differential for cases and controls,
hence the relative effect measures for IPD will be unaffected.
Previous studies using the Swedish Inpatient Registry, as
well as our own patient record reviews in this cohort, indicate
that around 80–95% of the diagnoses are correct [7]. Any
misclassiﬁcation of co-morbidity before admission for invasive
FIG. 1. Odds ratios and 95% conﬁdence intervals for invasive pneumococcal disease (IPD) in patients with chronic obstructive pulmonary disease
(COPD) or asthma, according to time since last hospital stay for COPD or asthma (left), age group (centre) and number of hospital visits for COPD
or asthma (right), compared with individuals without COPD or asthma, estimated using conditional logistic regression, adjusted for other
non-pulmonary co-morbidities conferring increased risk of IPD, total duration of previous hospital stay, level of education and socio-economic status.
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pneumococcal disease would presumably be non-differential
and, if anything, bias estimates downwards.
Models were adjusted for year of birth, gender and county
of residence through the matching procedure, as well as for
level of education, socio-economic status, and medical condi-
tions conferring susceptibility to IPD. Residual confounding
from factors such as co-morbid conditions only requiring
primary care or alcohol intake cannot be ruled out. The clinical
presentation was derived from discharge codes from the
Inpatient Registry, being less precise than chart reviews. The
proportion of IPD patients with no recorded focus is
comparable to that reported from some previous studies [6]
but greater than others [5,26].
Vaccination with 23-valent pneumococcal polysaccharide
vaccine (PPV23) was introduced in Sweden in 1985, and has
been recommended by the Board of Health and Welfare since
1994 for individuals aged 65 and over, and those with certain
chronic medical conditions, such as chronic pulmonary disease.
Vaccination coverage is generally regarded to be low, although
it has not been estimated on a national level. According to
regional sales statistics, about 600–800 doses of PPV/100 000
inhabitants (all ages) were distributed annually in the county of
Skane in the period 1997–2001 [27]. Conjugated pneumococ-
cal vaccine has been included in the routine childhood
immunization programme since 2009. Vaccine coverage in
patients with chronic pulmonary disease is presumably higher
than in healthy subjects, especially in younger age groups
where general vaccination is not recommended. This could
have biased estimates of the risk of IPD downwards.
In line with several previous studies, we did not ﬁnd an
increased 28-day or 90-day mortality risk following IPD among
those with previous records of COPD, asthma, pulmonary
ﬁbrosis or bronchiectasis [3,28,29]. Our exposure deﬁnition
was based on discharge codes, which does not allow any
detailed analyses of the mediators of death from IPD. On the
other hand, if an underlying pulmonary disease were associated
with increased case-fatality rate, this would be an upstream
determinant of pneumococcal disease severity and adjusting
for other (downstream) severity markers, e.g. leucocyte count,
hypothermia, would obscure the overall effect because these
would be on the same biological pathway.
In conclusion, we have conducted a population-based study
of IPD cases spanning almost 18 years, covering the residents
of southern Sweden, an area with around 1.6 million inhab-
itants. We believe that the results are generalizable to many
settings, although differences in population composition and
thresholds for hospitalization are likely to inﬂuence the results.
Several, but not all, chronic pulmonary diseases increase the
risk of acquiring IPD, although the risk of death following IPD
seems not to be affected.
Acknowledgements
We would like to express our gratitude to Maria Anderberg,
Lena Dillner, Joakim Dillner and Bj€orn Nilsson at the Depart-
ment of Microbiology, Malm€o, and Arne Andersson at the
Department ofMicrobiology, Lund, for identifying the IPD cases.
The results from the present study have been presented as a
poster at the ERSAnnual Congress, 3 September 2012 in Vienna.
Transparency Declaration
Professor Gunnar Engstr€om was formerly employed as a
senior epidemiologist by AstraZeneca R&D. Claes-G€oran
L€ofdahl has been paid for lectures by AstraZeneca, Boehrin-
ger-Ingelheim, GlaxoSmithKline, Meda, Novartis, Pﬁzer and
Takeds; taken part in and been paid for ad hoc advisory boards
for the same companies; and has had institutional support as
unrestricted grants from AstraZeneca, Boehringer-Ingelheim
and GlaxoSmithKline.
Funding
This study was supported by grants from the Swedish Research
Council (project no. 20674), the Swedish Heart and Lung
Foundation (project no. 20080246), the Swedish Government
Funds for Clinical Research (ALF), the foundations of Bergh,
Crafoord, Greta and Johan Kock, Alfred O¨sterlund and The
Royal Physiographic Society in Lund. The funders played no role
in the design of the study, data collection or analysis, decision to
publish, or preparation of the manuscript.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Appendix S1. The speciﬁc codes according to the
international classiﬁcation of Diseases.
References
1. Epidemiologiskarsrapport. http://www.Smi.Se/upload/publikationer/ep-
idemiologisk-%c3%a5rsrapport-2010-2011-1-5.Pdf. In: Control. SIfCD,
ed. 2011-1-5 edn 2010.
2. Talbot TR, Hartert TV, Mitchel E et al. Asthma as a risk factor
for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082–
2090.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 1148–1154
CMI Inghammar et al. Pneumococcal patients with pulmonary disorder 1153
3. Klemets P, Lyytikainen O, Ruutu P, Ollgren J, Nuorti JP. Invasive
pneumococcal infections among persons with and without underlying
medical conditions: implications for prevention strategies. BMC Infect
Dis 2008; 8: 96.
4. Kyaw MH, Rose CE Jr, Fry AM et al. The inﬂuence of chronic illnesses
on the incidence of invasive pneumococcal disease in adults. J Infect Dis
2005; 192: 377–386.
5. Kalin M, Ortqvist A, Almela M et al. Prospective study of prognostic
factors in community-acquired bacteremic pneumococcal disease in 5
countries. J Infect Dis 2000; 182: 840–847.
6. Laurichesse H, Romaszko JP, Nguyen LT et al. Clinical characteristics
and outcome of patients with invasive pneumococcal disease,
Puy-de-Dome, France, 1994–1998. Eur J Clin Microbiol Infect Dis 2001;
20: 299–308.
7. Ludvigsson JF, Andersson E, Ekbom A et al. External review and
validation of the Swedish National Inpatient Register. BMC Public Health
2011; 11: 450.
8. Inghammar M, Engstrom G, Lofdahl CG, Egesten A. Validation of a
COPD diagnosis from the Swedish Inpatient Registry. Scand J Public
Health 2012; 8: 773–776.
9. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic
obstructive pulmonary disease. N Engl J Med 2008; 359: 2355–2365.
10. Berenson CS, Wrona CT, Grove LJ et al. Impaired alveolar macro-
phage response to Haemophilus antigens in chronic obstructive lung
disease. Am J Respir Crit Care Med 2006; 174: 31–40.
11. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B.
Toll-like receptor 2 expression is decreased on alveolar macrophages
in cigarette smokers and COPD patients. Respir Res 2005; 6: 68.
12. Nuorti JP, Butler JC, Farley MM et al. Cigarette smoking and invasive
pneumococcal disease. Active bacterial core surveillance team. N Engl J
Med 2000; 342: 681–689.
13. Statens folkh€alsoinstitut (2011f). Nationella folkh€alsoenk€aten: Levnadsva-
nor: Tobaksvanor. H€amtad 2011-09-26, fran http://www.Fhi.Se/statis-
tik-uppfoljning/nationella-folkhalsoenkaten/levnadsvanor/tobaksvanor/.
14. Lofdahl CG, Tilling B, Ekstrom T, Jorgensen L, Johansson G, Larsson K.
COPD health care in Sweden – a study in primary and secondary care.
Respir Med 2010; 104: 404–411.
15. Lindberg A, Larsson LG, Muellerova H, Ronmark E, Lundback B.
Up-to-date on mortality in COPD – report from the Olin COPD
study. BMC Pulm Med 2012; 12: 1.
16. Raghu G, Collard HR, Egan JJ et al. An ofﬁcial ats/ers/jrs/alat
statement: idiopathic pulmonary ﬁbrosis: evidence-based guidelines
for diagnosis and management. Am J Respir Crit Care Med 2011; 183:
788–824.
17. Statement on sarcoidosis. Joint statement of the American Thoracic
Society (ATS), the European Respiratory Society (ERS) and the World
Association of Sarcoidosis and other Granulomatous Sisorders (WA-
SOG) adopted by the ATS board of directors and by the ERS executive
committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736–
755.
18. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in
patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954–963.
19. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids
and the risk of pneumonia in chronic obstructive pulmonary disease: a
meta-analysis. Arch Intern Med 2009; 169: 219–229.
20. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled
corticosteroids in patients with stable chronic obstructive pulmonary
disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407–
2416.
21. Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of
pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374:
712–719.
22. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of
idiopathic pulmonary ﬁbrosis: incidence, risk factors and outcome. Eur
Respir J 2011; 37: 356–363.
23. Richter AG, Stockley RA, Harper L, Thickett DR. Pulmonary infection
in Wegener granulomatosis and idiopathic pulmonary ﬁbrosis. Thorax
2009; 64: 692–697.
24. Park JH, Kim DS, Park IN et al. Prognosis of ﬁbrotic interstitial
pneumonia: idiopathic versus collagen vascular disease-related sub-
types. Am J Respir Crit Care Med 2007; 175: 705–711.
25. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration
in patients with idiopathic pulmonary ﬁbrosis: causes and assessment.
Am J Med 1990; 88: 396–404.
26. Berg S, Trollfors B, Persson E et al. Serotypes of Streptococcus
pneumoniae isolated from blood and cerebrospinal ﬂuid related to
vaccine serotypes and to clinical characteristics. Scand J Infect Dis 2006;
38: 427–432.
27. Spindler C, Hedlund J, Jasir A, Normark BH, Ortqvist A. Effects of a
large-scale introduction of the pneumococcal polysaccharide vaccine
among elderly persons in Stockholm, Sweden. Vaccine 2008; 26: 5541–
5546.
28. Mirzanejad Y, Roman S, Talbot J, Nicolle L. Pneumococcal bacteremia
in two tertiary care hospitals in Winnipeg, Canada. Pneumococcal
bacteremia study group. Chest 1996; 109: 173–178.
29. Jansen AG, Rodenburg GD, van der Ende A et al. Invasive pneumo-
coccal disease among adults: associations among serotypes, disease
characteristics, and outcome. Clin Infect Dis 2009; 49: e23–e29.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 1148–1154
1154 Clinical Microbiology and Infection, Volume 19 Number 12, December 2013 CMI
